Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors

Chung-Jye Hung, David G. Ginzinger, Raza Zarnegar, Hajime Kanauchi, Mariwil G. Wong, Electron Kebebew, Orlo H. Clark, Quan Yang Duh

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

In contrast to vascular endothelial growth factor (VEGF), which stimulates angiogenesis, VEGF-C is thought to stimulate lymphangiogenesis. The role of VEGF-C in thyroid cancer pathogenesis has not been clarified. One might expect a different pattern of VEGF-C expression in the various types of thyroid cancer because of their different means of metastases. In this investigation, we determined whether the differential expression of VEGF-C might explain the different propensity to lymph node metastasis in thyroid cancers. One hundred eleven normal and neoplastic thyroid tissues were analyzed by real-time quantitative PCR. Papillary thyroid cancers had a higher VEGF-C expression than other thyroid malignancies (P < 0.0005 ANOVA). Among the normal thyroid tissues from patients with malignant or benign thyroid diseases, there was no significant difference in VEGF-C expression. Paired comparison of VEGF-C expression between thyroid cancers and normal thyroid tissues from the same patients showed a significant increase of VEGF-C expression in papillary thyroid cancer (1.10 ± 0.41 vs. 0.70 ± 0.13; P = 0.001) and a significant decrease of VEGF-C expression in medullary thyroid cancer (0.11 ± 0.13 vs. 0.78 ± 0.29; P = 0.001). In contrast, there was no significant difference of VEGF-C expression between cancer and normal tissues in other types of thyroid cancer. In summary, VEGF-C expression is increased in papillary thyroid cancer, compared with paired normal thyroid tissues, but not in other thyroid cancers that are also prone to lymph node metastasis. The lymphangiogenic role of VEGF-C in thyroid cancers therefore appears to be complex and other factors are likely to be also involved.

Original languageEnglish
Pages (from-to)3694-3699
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number8
DOIs
Publication statusPublished - 2003 Aug 1

Fingerprint

Vascular Endothelial Growth Factor C
Tumors
Thyroid Gland
Thyroid Neoplasms
Neoplasms
Tissue
Neoplasm Metastasis
Lymph Nodes
Lymphangiogenesis
Matched-Pair Analysis
Thyroid Diseases
Analysis of variance (ANOVA)
Vascular Endothelial Growth Factor A
Real-Time Polymerase Chain Reaction
Analysis of Variance

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Hung, Chung-Jye ; Ginzinger, David G. ; Zarnegar, Raza ; Kanauchi, Hajime ; Wong, Mariwil G. ; Kebebew, Electron ; Clark, Orlo H. ; Duh, Quan Yang. / Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. In: Journal of Clinical Endocrinology and Metabolism. 2003 ; Vol. 88, No. 8. pp. 3694-3699.
@article{c9d94a66ec424346a02906dfb0ad3c84,
title = "Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors",
abstract = "In contrast to vascular endothelial growth factor (VEGF), which stimulates angiogenesis, VEGF-C is thought to stimulate lymphangiogenesis. The role of VEGF-C in thyroid cancer pathogenesis has not been clarified. One might expect a different pattern of VEGF-C expression in the various types of thyroid cancer because of their different means of metastases. In this investigation, we determined whether the differential expression of VEGF-C might explain the different propensity to lymph node metastasis in thyroid cancers. One hundred eleven normal and neoplastic thyroid tissues were analyzed by real-time quantitative PCR. Papillary thyroid cancers had a higher VEGF-C expression than other thyroid malignancies (P < 0.0005 ANOVA). Among the normal thyroid tissues from patients with malignant or benign thyroid diseases, there was no significant difference in VEGF-C expression. Paired comparison of VEGF-C expression between thyroid cancers and normal thyroid tissues from the same patients showed a significant increase of VEGF-C expression in papillary thyroid cancer (1.10 ± 0.41 vs. 0.70 ± 0.13; P = 0.001) and a significant decrease of VEGF-C expression in medullary thyroid cancer (0.11 ± 0.13 vs. 0.78 ± 0.29; P = 0.001). In contrast, there was no significant difference of VEGF-C expression between cancer and normal tissues in other types of thyroid cancer. In summary, VEGF-C expression is increased in papillary thyroid cancer, compared with paired normal thyroid tissues, but not in other thyroid cancers that are also prone to lymph node metastasis. The lymphangiogenic role of VEGF-C in thyroid cancers therefore appears to be complex and other factors are likely to be also involved.",
author = "Chung-Jye Hung and Ginzinger, {David G.} and Raza Zarnegar and Hajime Kanauchi and Wong, {Mariwil G.} and Electron Kebebew and Clark, {Orlo H.} and Duh, {Quan Yang}",
year = "2003",
month = "8",
day = "1",
doi = "10.1210/jc.2003-030080",
language = "English",
volume = "88",
pages = "3694--3699",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

Hung, C-J, Ginzinger, DG, Zarnegar, R, Kanauchi, H, Wong, MG, Kebebew, E, Clark, OH & Duh, QY 2003, 'Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors', Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 8, pp. 3694-3699. https://doi.org/10.1210/jc.2003-030080

Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors. / Hung, Chung-Jye; Ginzinger, David G.; Zarnegar, Raza; Kanauchi, Hajime; Wong, Mariwil G.; Kebebew, Electron; Clark, Orlo H.; Duh, Quan Yang.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 8, 01.08.2003, p. 3694-3699.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors

AU - Hung, Chung-Jye

AU - Ginzinger, David G.

AU - Zarnegar, Raza

AU - Kanauchi, Hajime

AU - Wong, Mariwil G.

AU - Kebebew, Electron

AU - Clark, Orlo H.

AU - Duh, Quan Yang

PY - 2003/8/1

Y1 - 2003/8/1

N2 - In contrast to vascular endothelial growth factor (VEGF), which stimulates angiogenesis, VEGF-C is thought to stimulate lymphangiogenesis. The role of VEGF-C in thyroid cancer pathogenesis has not been clarified. One might expect a different pattern of VEGF-C expression in the various types of thyroid cancer because of their different means of metastases. In this investigation, we determined whether the differential expression of VEGF-C might explain the different propensity to lymph node metastasis in thyroid cancers. One hundred eleven normal and neoplastic thyroid tissues were analyzed by real-time quantitative PCR. Papillary thyroid cancers had a higher VEGF-C expression than other thyroid malignancies (P < 0.0005 ANOVA). Among the normal thyroid tissues from patients with malignant or benign thyroid diseases, there was no significant difference in VEGF-C expression. Paired comparison of VEGF-C expression between thyroid cancers and normal thyroid tissues from the same patients showed a significant increase of VEGF-C expression in papillary thyroid cancer (1.10 ± 0.41 vs. 0.70 ± 0.13; P = 0.001) and a significant decrease of VEGF-C expression in medullary thyroid cancer (0.11 ± 0.13 vs. 0.78 ± 0.29; P = 0.001). In contrast, there was no significant difference of VEGF-C expression between cancer and normal tissues in other types of thyroid cancer. In summary, VEGF-C expression is increased in papillary thyroid cancer, compared with paired normal thyroid tissues, but not in other thyroid cancers that are also prone to lymph node metastasis. The lymphangiogenic role of VEGF-C in thyroid cancers therefore appears to be complex and other factors are likely to be also involved.

AB - In contrast to vascular endothelial growth factor (VEGF), which stimulates angiogenesis, VEGF-C is thought to stimulate lymphangiogenesis. The role of VEGF-C in thyroid cancer pathogenesis has not been clarified. One might expect a different pattern of VEGF-C expression in the various types of thyroid cancer because of their different means of metastases. In this investigation, we determined whether the differential expression of VEGF-C might explain the different propensity to lymph node metastasis in thyroid cancers. One hundred eleven normal and neoplastic thyroid tissues were analyzed by real-time quantitative PCR. Papillary thyroid cancers had a higher VEGF-C expression than other thyroid malignancies (P < 0.0005 ANOVA). Among the normal thyroid tissues from patients with malignant or benign thyroid diseases, there was no significant difference in VEGF-C expression. Paired comparison of VEGF-C expression between thyroid cancers and normal thyroid tissues from the same patients showed a significant increase of VEGF-C expression in papillary thyroid cancer (1.10 ± 0.41 vs. 0.70 ± 0.13; P = 0.001) and a significant decrease of VEGF-C expression in medullary thyroid cancer (0.11 ± 0.13 vs. 0.78 ± 0.29; P = 0.001). In contrast, there was no significant difference of VEGF-C expression between cancer and normal tissues in other types of thyroid cancer. In summary, VEGF-C expression is increased in papillary thyroid cancer, compared with paired normal thyroid tissues, but not in other thyroid cancers that are also prone to lymph node metastasis. The lymphangiogenic role of VEGF-C in thyroid cancers therefore appears to be complex and other factors are likely to be also involved.

UR - http://www.scopus.com/inward/record.url?scp=0042384574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042384574&partnerID=8YFLogxK

U2 - 10.1210/jc.2003-030080

DO - 10.1210/jc.2003-030080

M3 - Article

VL - 88

SP - 3694

EP - 3699

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -